Treatment sequencing and the benefits of DMTs

touchPANEL DISCUSSION for touchNEUROLOGY

Listen to a panel of leading multiple sclerosis (MS) experts discuss their perspectives on the benefits of disease-modifying therapies (DMTs) in MS, and current approaches to treatment sequencing. 

The experts

• Prof. Gavin Giovannoni (Chair), Blizard Institute, Queen Mary University of London, UK
• Prof. Eva Havrdová, General Faculty Hospital, Charles University in Prague, Czech Republic
• Prof. Patrick Vermersch, Lille University Hospital, France

This touchPODCAST is for HCPs only. 

This activity is funded by an unrestricted independent educational grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchneurology.com/cme/treatment-sequencing-in-ms-the-benefits-of-dmts/